Creating new antiviral treatments for deadly filoviruses like Ebola
Official title: Development of antibody drug conjugates as pan-filo antivirals
Funded at Microbiotix, INC · NIH-10911352 · Data updated 2026-11-12
This study is working on new treatments for serious viruses that cause severe fevers by creating special antibodies that can fight different strains of the virus, and it aims to find better ways to stop the virus from entering human cells before testing these treatments in animals.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Microbiotix, INC NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project start | August 21, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $286,708 |
| NIH project number | 5R43AI179343-02 |
| Project ID | NIH-10911352 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals at high risk of exposure to filoviruses, such as healthcare workers or those in outbreak regions.
✕Less likely to help
Patients who are not at risk of filovirus infections or those with existing effective treatments may not benefit from this research.
What this research studies
This research focuses on developing innovative antibody drug conjugates to combat filoviruses, which cause severe hemorrhagic fevers with high mortality rates. The approach involves creating bispecific antibodies that can target multiple strains of the virus, enhancing their effectiveness. By disrupting the viral entry mechanism into human cells, the research aims to provide a broader and more effective treatment option compared to existing therapies. The project will utilize animal models to test the efficacy of these new treatments before considering human applications.
Why it matters
Potential benefit: If successful, this research could lead to effective antiviral treatments for filovirus infections, potentially saving lives during outbreaks.
How similar studies have gone: Previous research has shown promise in developing antiviral therapies for filoviruses, but this approach using bispecific antibodies is relatively novel.
Where this research is happening
-
Microbiotix, INC
Worcester, United States Active
Researchers
- Principal investigator: Liu, Gai — Microbiotix, INC
- Study coordinator: Liu, Gai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.